Clinical significance of mTOR and eIF4E expression in invasive ductal carcinoma

Tumori

Volumn 100, Issue 5, 2014, Pages 541-546

  Hu, Aixia ^a   Sun, Miaomiao ^b   Yan, Dong ^a   Chen, Kuisheng ^c  

^a Department of Pathology Central Hospital of Shangqiu City   (China)

^b Henan Tumor Hospital   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

4E binding protein; Breast invasive ductal carcinoma; Eukaryotic initiation factor 4E; Expression; Mammalian target of rapamycin; Metastasis

Indexed keywords

INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; CARRIER PROTEIN; EIF4EBP1 PROTEIN, HUMAN; EIF4EBP2 PROTEIN, HUMAN; EIF4EBP3 PROTEIN, HUMAN; INITIATION FACTOR; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; BREAST; BREAST BIOPSY; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST SURGERY; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROTEIN TRANSPORT; SECONDARY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARRIER PROTEINS; EUKARYOTIC INITIATION FACTOR-4E; EUKARYOTIC INITIATION FACTORS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PHOSPHOPROTEINS; PROGNOSIS; PROTEIN TRANSPORT; TOR SERINE-THREONINE KINASES;

EID: 84916927936     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/1660.18176     Document Type: Article

References (19)

1. Liu W, Gu DM, Liu L, Jin XH, Xu XT:1. Association between the BRCA2 codon polymorphisms and prognosis in breast cancer. Chin J Clin Exp Pathol, 29: 247-249, 2013 (In Chinese).
2. Zablocki GJ, Ruzycki PA, Overturf MA, Palla S, Reddy GB, Petrash JM: Aldose reductase-mediated induction of epi-thelium-to-mesenchymal transition (EMT) in lens. Chem Biol Interact, 191: 351-356, 2011.
3. Simpson PT, Reis-filho JS, Lakhani SR: Breast pathology: beyond morphology. Semin Diagn pathol, 27: 91-96, 2010.
4. Peihong S, Perry F: Expression of nm23, MMP-2, TIMP breast neoplasm in Zhengzhou Center Hospital, China. Ethiop Med J, 45: 79-83, 2007.
5. Pectasides D, Pectasides E, Economopoulos T: Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev, 33: 177-190, 2007.
6. Wang Tao, Jiang ZF: Advancement, dilemma and perspective in molecular targeted therapy of breast cancer. Chin J Breast Dis, 5: 517-524, 2011 (In Chinese).
7. Creighton CJ: A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene, 26: 4648-4655, 2007.
8. Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW, Tsao MS: Immunhistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer, 8: 43, 2008.
9. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M: Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res, 13: 4795-4799, 2007.
10. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate, 66: 1203-1212, 2006.
11. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M: mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res, 10: 8421-8425, 2007.
12. Kang LF, Li YH, Zhang XH, Wu WX, MA YM, Zhang JY: Expression of mTOR and eIF4E and their clinical implications in endometrial endometrioid adenocarcinoma. Chin J Clin Exp Pathol, 27: 71-74, 2011 (In Chinese).
13. Hynes NE, Boulay A: The mTOR Pathway in Breast Cancer. J Mammary Gland Biol Neoplasia, 11: 53-61, 2006.
14. Laurent-puiq P, Aqostini J, Maley K: Colorectaloncogenesis. Bull Cancer, 97: 1311-1321, 2010.
15. Yang Y: Expression and significance of mTOR and eIF4E in human colorectal carcinoma. Contemp Med, 19: 28-30, 2013 (In Chinese).
16. Presneau N, Shalby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirabosco R, Flanagan AM: Potential therapeutic targets for chordoma: p13k/Akt/TSC1/TSC2/mTOR pathway. Br J Cancer, 100: 1406-1411, 2009.
17. Memmott RM, Dennis PA: Akt-dependent and independent mechanisms of mTOR regulation in cancer. Cell Signal, 21: 656-664, 2009.
18. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Clin Oncol, 27: 2630-2637, 2009.
19. Johnson SM, Gulhati P, Arrieta I, Wang X, Uchida T, Gao T, Evers BM: Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anti Cancer Res, 29: 3185-3190, 2009.